Herein, we have shown that an archaeosome-based vaccine alone will induce OVA-CD8+ T cells capable of providing short-term protection in therapy against solid subcutaneous B16-OVA in mice and that this correlated with a high level of PD-1 expression on tumor-infiltrating OVA-CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.